Apexigen Adds $65 Million to C Round in Funding Led by China Investors
publication date: Mar 25, 2020
Apexigen, a Bay Area clinical-stage biopharma, closed a $65 million second tranche of its C round that was led by two China investment firms, Decheng and Oceanpine. Last year, Apexigen raised $58 million in the first arm of the C round. Apexigen is developing immunotherapies for oncology, including APX005M, a mAb targeting CD40. Binding of APX005M to CD40 on antigen presenting cells (dendritic cells, monocytes and B-cells) is expected to activate both innate and adaptive immune systems. APX005M is currently being tested in several Phase II trials in multiple solid tumor cancers. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.